. 2021 Jan 13;11(1):e288. doi: 10.1002/ctm2.288

TABLE 3.

Tyrosine kinases targeting agents in clinical trials

Drug/description	Sponsors	Phase/status	Tumor type	Treatment	Clinical trials.govIdentifier	First received
CSF‐1R/CSF‐1 inhibitor
Emactuzumab/RG7155/RO5509554 (anti‐ CSF1R antibody)	M.D. Anderson Cancer Center	2 ^b	Ovarian, fallopian tube, or primary peritoneal cancer	With paclitaxel and bevacizumab	NCT02923739	2016‐10‐05
	Hoffmann‐La Roche	1 ^b	Advanced or metastatic solid cancers	With atezolizumab	NCT02323191	2014‐12‐23
	Hoffmann‐La Roche	1 ^a	Advanced solid tumors	With RO7009789	NCT02760797	2016‐05‐04
	Hoffmann‐La Roche	1 ^a	Advanced solid tumors	Monotherapy	NCT01494688 ³⁷⁸	2011‐12‐19
FPA008/Cabiralizumab (anti‐CSF1R antibody)	Bristol‐Myers Squibb	2 ^b	Advanced pancreatic cancer	With nivolumab	NCT03336216	2017‐12‐08
	Five Prime Therapeutics	1/2 ^b	Tenosynovial giant cell tumor	Monotherapy	NCT02471716	2015‐06‐15
	Five Prime Therapeutics	1a/b ^b	Advanced lung cancer, head and neck cancer, pancreatic cancer, ovarian cancer, renal cell carcinoma, and malignant glioma	With nivolumab	NCT02526017	2015‐08‐18
	Bristol‐Myers Squibb	1 ^a	Advanced malignancies	With nivolumab	NCT03158272	2017‐05‐18
LY3022855/IMC‐CS4 (anti‐CSF1R antibody)	Eli Lilly and Company	1a/b ^a	Solid tumor	With durvalumab or tremelimumab	NCT02718911	2016‐03‐24
	Dana‐Farber Cancer Institute	1/2 ^b	Melanoma	With vemurafenib and cobimetinib	NCT03101254	2017‐04‐05
	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	1 ^b	Pancreatic cancer	With GVAX, cyclophosphamide, and pembrolizumab	NCT03153410	2017‐05‐15
	Eli Lilly and Company	1 ^a	Advanced breast or prostate cancer	Monotherapy	NCT02265536	2014‐10‐16
	Eli Lilly and Company	1 ^a	Advanced solid tumors	Monotherapy	NCT01346358	2011‐05‐03
AMG820 (anti‐CSF1R antibody)	Amgen	1b/2 ^a	Pancreatic cancer, colorectal cancer and non‐small cell lung cancer	With pembrolizumab	NCT02713529	2016‐03‐18
	Amgen	1 ^a	Advanced solid tumors	Monotherapy	NCT01444404	2011‐09‐30
MCS110 (anti‐ CSF1 antibody)	Yonsei University	2 ^b	Squamous cell carcinoma	With PDR001	NCT03785496	2018‐12‐24
	Seoul National University Hospital	2 ^b	Gastric cancer	With PDR001	NCT03694977	2018‐10‐03
	Novartis Pharmaceuticals	2 ^b	Advanced triple‐negative breast cancer	With carboplatin and gemcitabine	NCT02435680	2015‐05‐06
	Dana‐Farber Cancer Institute	1/2 ^b	Melanoma	With dabrafenib and trametinib	NCT03455764	2018‐03‐07
	Novartis Pharmaceuticals	1b/2 ^b	Triple‐negative breast cancer, pancreatic carcinoma, melanoma, and endometrial carcinoma	With PDR001	NCT02807844	2016‐06‐21
JNJ‐40346527 (CSF‐1R kinase inhibitor)	OHSU Knight Cancer Institute	2 ^b	Relapsed/Refractory acute myeloid leukemia	Monotherapy	NCT03557970	2018‐06‐15
	Janssen Research & Development	1/2 ^a	Relapsed or refractory Hodgkin lymphoma	Monotherapy	NCT01572519	2012‐04‐06
	M.D. Anderson Cancer Center	1 ^b	Prostate cancer	Monotherapy	NCT03177460	2017‐06‐06
Pexidartinib/PLX3397 (CSF‐1R kinase inhibitor)	Daiichi Sankyo	3 ^b	Pigmented villonodular synovitis or giant cell tumor of the tendon sheath	Monotherapy	NCT02371369 ³⁷⁹	2015‐02‐25
	Daiichi Sankyo	2 ^a	Hodgkin lymphoma	Monotherapy	NCT01217229	2010‐10‐08
	Daiichi Sankyo	1/2 ^b	Melanoma	Monotherapy	NCT02975700	2016‐12‐29
	National Cancer Institute	1/2 ^b	Plexiform neurofibroma, precursor cell lymphoblastic leukemia lymphoma and acute prolymphocytic leukemia	Monotherapy	NCT02390752	2015‐03‐18
	Hope Rugo, MD	1b/2 ^a	Metastatic breast cancer	With Eribulin	NCT01596751	2012‐05‐11
	Daiichi Sankyo	1b/2 ^b	Glioblastoma	With radiation therapy and temozolomide	NCT01790503	2013‐02‐13
	Daiichi Sankyo	1/2 ^a	Acute myeloid leukemia	Monotherapy	NCT01349049 ³⁸⁰	2011‐05‐06
	Gulam Manji	1 ^b	Sarcoma and malignant peripheral nerve sheath tumors	With sirolimus	NCT02584647	2015‐10‐22
	Plexxikon	1 ^a	Advanced solid tumors	With Paclitaxel	NCT01525602	2012‐02‐03
	Daiichi Sankyo	1 ^b	Solid tumor	Monotherapy	NCT01004861 ³⁷³	2009‐10‐30
	Centre Leon Berard	1 ^a	Advanced and metastatic colorectal cancer and pancreatic cancer	With durvalumab	NCT02777710	2016‐05‐19
ARRY‐382 (CSF‐1R kinase inhibitor)	Array Biopharma	1 ^a	Metastatic cancer	Monotherapy	NCT01316822	2011‐03‐16
	Array BioPharma	1b/2 ^a	Advanced solid tumors	With pembrolizumab	NCT02880371	2016‐08‐26
BLZ945 (CSF‐1R kinase inhibitor)	Novartis Pharmaceuticals	1/2 ^b	Advanced solid tumors	With PDR001	NCT02829723	2016‐07‐12
DCC‐3014 (CSF‐1R kinase inhibitor)	Deciphera Pharmaceuticals	1/2 ^b	Malignant solid tumors and tenosynovial giant cell tumor	Monotherapy	NCT03069469	2017‐03‐03
ENMD‐2076 (CSF‐1R kinase inhibitor)	University Health Network, Toronto	2#^a	Ovarian clear cell carcinoma	Monotherapy	NCT01914510	2013‐08‐02
	University Health Network, Toronto	2 ^a	Advanced/metastatic soft tissue sarcoma	Monotherapy	NCT01719744	2012‐11‐01
	CASI Pharmaceuticals	2 ^a	Advanced adult hepatocellular carcinoma and advanced fibrolamellar carcinoma	Monotherapy	NCT02234986	2014‐09‐09
	CASI Pharmaceuticals	2 ^a	Triple‐negative breast cancer	Monotherapy	NCT01639248 ³⁸¹	2012‐07‐12
RON inhibitor
Narnatumab/ IMC‐RON8 (anti‐RON antibody)	Eli Lilly and Company	1 ^a	Solid tumors	Monotherapy	NCT01119456	2010‐05‐07
ASLAN002/BMS 777607 (RON kinase inhibitor)	Bristol‐Myers Squibb	1/2 ^a	Advanced or metastatic solid tumor	Monotherapy	NCT00605618	2008‐01‐31
	Aslan Pharmaceuticals	1 ^a	Advanced or metastatic solid tumor	Monotherapy	NCT01721148 ³⁸²	2012‐12‐04
Crizotinib/ PF‐02341066 (RON kinase inhibitor)	UNICANCER	2 ^b	Hematologic cancers and solid tumors and metastatic cancer	Monotherapy	NCT02034981 ³⁸³	2014‐01‐14
	Dana‐Farber Cancer Institute	1 ^b	Castration‐resistant prostate cancer	With enzalutamide	NCT02207504	2014‐08‐04
Foretinib/GSK1363089 (RON kinase inhibitor)	NCIC Clinical Trials Group	2 ^a	Recurrent breast cancer	Monotherapy	NCT01147484 ³⁸⁴	2010‐06‐22
	GlaxoSmithKline	2 ^a	Head and neck cancer	Monotherapy	NCT00725764	2008‐07‐30
	GlaxoSmithKline	2 ^a	Papillary Renal‐Cell Carcinoma	Monotherapy	NCT00726323 ³⁸⁵	2008‐07‐31
	GlaxoSmithKline	2 ^a	Metastatic gastric carcinoma	Monotherapy	NCT00725712 ³⁸⁶	2008‐07‐30
	GlaxoSmithKline	1 ^a	Solid Tumors	Monotherapy	NCT00742131	2008‐08‐27
	GlaxoSmithKline	1 ^a	Hepatocellular carcinoma	Monotherapy	NCT00920192 ³⁸⁷	2009‐06‐15

Source: clinicaltrials.gov.

^{^a}

Completed stage.

^{^b}

Ongoing stage, including both recruiting and nonrecruiting stages.